Filing Details
- Accession Number:
- 0001127602-16-049647
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-04-21 13:28:17
- Reporting Period:
- 2016-04-19
- Filing Date:
- 2016-04-21
- Accepted Time:
- 2016-04-21 13:28:17
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
882095 | Gilead Sciences Inc | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1334682 | H Gregg Alton | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | Evp, Corp & Med Affairs | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-04-19 | 35,874 | $26.99 | 177,964 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-04-19 | 35,874 | $100.02 | 142,090 | No | 4 | S | Direct | |
Common Stock | Disposition | 2016-04-19 | 4,126 | $100.00 | 137,964 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2016-04-19 | 35,874 | $0.00 | 35,874 | $26.99 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
64,126 | 2018-07-30 | No | 4 | M | Direct |
Footnotes
- The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- Options vest over a five year period with 20% vesting July 30, 2009, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, and will be fully vested on July 30, 2013.
- Sale prices reported for the transactions reported here range from $100.00 to $100.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.